Naloxone

April 11, 2024 | Controlled Substances, Criminal Justice, Harm Reduction, Medication Assisted Treatment (MAT), Naloxone, Opioid Antagonists, Opioids, Prescription Drugs, Public Health, Public Safety, Recovery, Reports & Studies, Substance Abuse, Treatments

The Addiction and Public Policy Initiative at the O’Neill Institute for National and Global Health Law was established in 2018 through a generous grant from Arnold Ventures. Housed at Georgetown Law, the Addiction and Public Policy Initiative works at the intersection of public health and the law to advance a public health approach to substance use disorder and the overdose epidemic through legal and policy strategies that promote evidence-based treatment, harm reduction, and recovery. This reports highlights O'Neill's accomplishments over the last five years....

October 16, 2023 | Controlled Substances, First Responders, Legal & Legislative Research, Naloxone, Opioid Antagonists, Opioid Antagonists, Opioids, Public Health, Public Safety, Substance Abuse

In an effort to save lives, states have implemented laws to make it easier for first responders and the general public to obtain opioid antagonists, such as naloxone. Additionally, to encourage people to assist an individual who is or may be suffering an overdose, the majority of states also enacted laws which protect laypeople who administer opioid antagonists, in good faith, in an emergency from civil and/or criminal liability. The Legislative Analysis and Public Policy Association (LAPPA) undertook an extensive research project to determine the current status of opioid antagonist access laws throughout the United States, including the District of Columbia and all U.S. territories. As of August 2020, all 50 states and the District of Columbia have some form of an opioid antagonist access law. ...

February 22, 2023 | Controlled Substances, Harm Reduction, Innovative Initiatives, Naloxone, Opioid Antagonists, Opioids, Prescription Drugs, Public Health, Recovery, Substance Abuse, Treatments

In the beginning of 2022, the West Virginia Drug Intervention Institute, the West Virginia Collegiate Recovery Network, and Marshall University, a public research university in Huntington, West Virginia, launched an overdose prevention initiative on every public and private college campus in West Virginia. The program, entitled, “Be The One” focuses on opioid overdose prevention from a bystander’s perspective, encouraging students, staff, and faculty to “be the one” to save a life....

February 8, 2022 | Controlled Substances, Criminal Justice, Harm Reduction, Medication Assisted Treatment (MAT), Naloxone, Opioids, Prescription Drugs, Public Health, Recovery, Substance Abuse, Toolkits, Treatments

The 2022 AMA-Manatt Toolkit builds on a previously published roadmap by providing actionable resources that states can use to take specific actions in six policy areas: (1) Increase access to evidence-based treatments to help patients with a substance use disorder (SUD); (2) Ensure access to addiction medicine, psychiatry, and other trained physicians; (3) Enforce mental health and substance use disorder (SUD) parity laws; (4) Improve access to multidisciplinary, multimodal care for patients with pain; (5) Expand harm reduction efforts to reduce death and disease; and (6) Improve monitoring and evaluation....

November 16, 2021 | Controlled Substances, First Responders, Harm Reduction, Model Laws, Naloxone, Opioid Antagonists, Opioids, Public Health, Public Safety, Recovery, Substance Abuse, Treatments

LAPPA’s Model Expanded Access to Emergency Opioid Antagonists Act provides state officials with the means to increase the ability of their citizens to access and use life-saving emergency opioid antagonists. The Centers for Disease Control and Prevention estimates that over 934,000 Americans died from a fatal overdose involving an opioid between 1999 and 2020. Opioid antagonists, such as naloxone, can be used during emergencies to reverse opioid overdoses and are effective in preventing fatal drug overdoses. This Act: (1) enables all citizens to access emergency opioid antagonists; (2) encourages citizens to obtain emergency opioid antagonists; (3) grants immunity to individuals who administer opioid antagonists; (4) requires physicians to co-prescribe an emergency opioid antagonist when prescribing an opioid to someone; (5) ensures that health insurance covers emergency opioid antagonists, like naloxone; (6) prohibits discriminatory life and health insurance practices related to the possession of emergency opioid antagonists; (7) provides increased access to opioid antagonists in educational institutions and correctional settings; (8) establishes a pilot program to increase bystander access to emergency opioid antagonists; and (9) promotes initiatives that educate citizens on the life-saving potential of emergency opioid antagonists....

April 19, 2021 | Controlled Substances, First Responders, Naloxone, Opioids, Prescription Drugs, Public Health, Public Safety, Reports & Studies

In recent years, some states have enacted Good Samaritan and Naloxone Access laws to help reduce overdose deaths and respond to opioid overdoses.The Comprehensive Addiction and Recovery Act of 2016 included a provision for GAO to review these laws. This report addresses the following: (1) the efforts ONDCP has taken to collect and disseminate information on Good Samaritan and Naloxone Access laws, (2) the extent to which states, territories, and D.C. have these laws and the characteristics of them, and (3) what research indicates concerning the effects of Good Samaritan laws.To answer these questions, GAO collected and reviewed ONDCP documents and interviewed agency officials. GAO also reviewed and analyzed selected characteristics of jurisdictions' Good Samaritan and Naloxone Access laws. Further, GAO conducted a literature review of empirical studies published from 2010 through May 2020 that examined the effects of Good Samaritan laws....